Cardiff Oncology rises on positive results from mid-stage cancer study

Cardiff Oncology

10/12/2024 12:39

** Shares of drug developer Cardiff Oncology  CRDF.O  rise
33.2% to $3.25 premarket
    ** Co announces positive initial data from its mid-stage
trial testing its experimental cancer drug, onvansertib, in
combination with standard-of-care treatment in patients with a
type of colorectal cancer
    ** Co says the combination treatment showed a 64% objective
response rate (ORR) in patients who were dosed with 30 mg of the
drug vs a 33% ORR in patients who received standard of care
alone
    ** ORR is the proportion of patients whose tumors reduced in
size or disappeared over a predefined amount of time
    ** Co says 30 mg dose demonstrated a higher ORR compared to
20 mg dose, with deeper tumor reduction in patients who received
the 30 mg dose
    ** The drug was well-tolerated and there have been no major
or unexpected toxicities observed - CRDF 
    ** Co says additional clinical data is expected in the first
half of 2025 
    ** Up to last close, stock up 64.9% YTD

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))